These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 22367656)
21. Effect of fish oil supplementation on quality of life in a general population of older Dutch subjects: a randomized, double-blind, placebo-controlled trial. van de Rest O; Geleijnse JM; Kok FJ; van Staveren WA; Olderikkert MG; Beekman AT; de Groot LC J Am Geriatr Soc; 2009 Aug; 57(8):1481-6. PubMed ID: 19549020 [TBL] [Abstract][Full Text] [Related]
22. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507 [TBL] [Abstract][Full Text] [Related]
24. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Veerman SR; Schulte PF; Begemann MJ; de Haan L Pharmacopsychiatry; 2014 Nov; 47(7):231-8. PubMed ID: 25121994 [TBL] [Abstract][Full Text] [Related]
25. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Bentsen H; Osnes K; Refsum H; Solberg DK; Bøhmer T Transl Psychiatry; 2013 Dec; 3(12):e335. PubMed ID: 24346133 [TBL] [Abstract][Full Text] [Related]
26. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. Chen AT; Chibnall JT; Nasrallah HA Ann Clin Psychiatry; 2015 Nov; 27(4):289-96. PubMed ID: 26554370 [TBL] [Abstract][Full Text] [Related]
36. The effect of mind-body and aerobic exercise on negative symptoms in schizophrenia: A meta-analysis. Vogel JS; van der Gaag M; Slofstra C; Knegtering H; Bruins J; Castelein S Psychiatry Res; 2019 Sep; 279():295-305. PubMed ID: 30879703 [TBL] [Abstract][Full Text] [Related]
37. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Begemann MJ; Dekker CF; van Lunenburg M; Sommer IE Schizophr Res; 2012 Nov; 141(2-3):179-84. PubMed ID: 22998932 [TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study. Wood SJ; Cocchi L; Proffitt TM; McConchie M; Jackson GD; Takahashi T; Pantelis C; McGorry PD; Berger GE Psychiatry Res; 2010 May; 182(2):180-2. PubMed ID: 20413278 [TBL] [Abstract][Full Text] [Related]
39. Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis. Fraguas D; Díaz-Caneja CM; Pina-Camacho L; Umbricht D; Arango C Schizophr Bull; 2019 Jan; 45(1):57-68. PubMed ID: 29370436 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis. Morsy S; Khalil SM; Doheim MF; Kamel MG; El-Basiony DSM; Ahmed Hassan HI; Eisa AA; Anh Ngoc CT; Dang NP; Hirayama K; Huy NT Acta Neuropsychiatr; 2019 Aug; 31(4):175-185. PubMed ID: 30890195 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]